ArriVent Biopharma: Truist Securities raises target price to $21 from $18
AVBP•Truist Securities raised its target price for ArriVent Biopharma to $21 from $18.
Related News
Millrose Properties Q3 net income hits record; raises AFFO outlook
MRP•
Nano Nuclear Energy and Hyundai Engineering sign MoU to advance Kronos MMR project
NNE•
Butterfly Network presents at UBS Global Healthcare Conference
BFLY•
Global Indemnity Group publishes update to financial calendar
GBLI•
Stryker joins Jefferies Global Healthcare Conference
SYK•